ENTRY       D12269            Mixture   Drug
NAME        Nirmatrelvir and ritonavir;
            Paxlovid (TN)
PRODUCT
  OTHER     PAXLOVID (Pfizer Laboratories Div Pfizer)
COMPONENT   Nirmatrelvir [DR:D12244], Ritonavir [DR:D00427]
CLASS       Antiviral
             DG03174  Anti-SARS-CoV-2 agent
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
REMARK      Therapeutic category: 6250
            ATC code: J05AE30
            Product: D12269<JP/US>
EFFICACY    Antiviral
  DISEASE   Coronavirus disease 2019 [DS:H02398]
METABOLISM  Enzyme: CYP3A4 [HSA:1576]
INTERACTION CYP inhibition: CYP3A [HSA:1576 1577 1551]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AE Protease inhibitors
                 J05AE30 Nirmatrelvir and ritonavir
                  D12269  Nirmatrelvir and ritonavir &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Antivirals, Coronavirus Agents
               Nirmatrelvir/ Ritonavir
                D12269  Nirmatrelvir and ritonavir
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D12269  Nirmatrelvir and ritonavir
            Drug groups [BR:br08330]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12269  Nirmatrelvir and ritonavir
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D12269  Nirmatrelvir and ritonavir
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               D12269  Nirmatrelvir and ritonavir
            Drug classes [BR:br08332]
             Antiviral
              DG03174  Anti-SARS-CoV-2 agent
               D12269  Nirmatrelvir and ritonavir
            Antimicrobials [BR:br08307]
             Antivirals
              Polyprotein cleavage inhibitor
               SARS-CoV 3C protease inhibitor
                D12269  Nirmatrelvir and ritonavir &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12269
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D12269
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12269
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12269
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D12269
DBLINKS     ChEBI: 192712
///
